Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.71 |
| ▸ | PDE4A | P27815 | 3/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.71 |
| ▸ | PDE2A | O00408 | 2/20 | 0.55 |
| ▸ | PDE1A | P54750 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212361 | 1.00 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6212364 | 1.00 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL16157200 | 0.85 | PDE3B (0.73) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10353457 | 0.84 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Ci-930 SCHEMBL6052113 | 0.83 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10371742 | 0.83 | PDE3B (0.63) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Ci-930 SCHEMBL10657390 | 0.82 | PDE3B (0.98) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10599509 | 0.82 | PDE3B (0.61) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10774409 | 0.81 | PDE3A (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10741553 | 0.80 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | claimed |
| US-6936618-B2 | Cystic fibrosis medicaments | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 2005-08-30 | — | — | US | disclosed |
| EP-1194148-B1 | TYPE V PDE-INHIBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | UNIV CARDIFF (GB) | 2005-03-02 | — | — | EP | disclosed |
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030229117-A1 | Cystic fibrosis medicaments | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 2003-12-11 | — | — | US | disclosed |
| US-6599907-B1 | Type V cyclic nucleotide phosphodiesterase inhibitor | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 2003-07-29 | — | — | US | disclosed |
| EP-1194148-A2 | CYSTIC FIBROSIS MEDICAMENTS | University of Wales College of Medicine (GB) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000064424-A2 | CYSTIC FIBROSIS MEDICAMENTS | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 2000-11-02 | — | — | WO | disclosed |
| US-5246928-A | Cardiovascular disorders | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-21 | — | — | US | disclosed |
| US-5066653-A | Cardiovascular disorders; bronchodilators; phosphodiesterase inhibitors | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-11-19 | — | — | US | disclosed |
| US-4906628-A | N-phenylpyridone type III phosphodiesterases | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-06 | — | — | US | disclosed |
| EP-0220044-A2 | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229117-A1 | Cystic fibrosis medicaments | CFTR, PDE3A, PDE4A | PDE3B 5/4885PDE3A 2/4885PDE4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.